electronRx Introduces Chronic Respiratory Disease Management App

electronRx has launched the pDx app for chronic respiratory disease (CRD) management. The app provides patients with a cardiopulmonary assessment device—engineered to medical grade standards—to measure lung function at home using a mobile phone, laptop or tablet.

The app enables clinicians to remotely assess cardiopulmonary function, track disease progression, and adjust treatment protocols to optimize therapeutic outcomes. By reducing the need for frequent hospital visits, pDx empowers patients to better manage their conditions while helping healthcare systems to streamline delivery and reduce the strain on resources.

“electronRx is dedicated to transforming the lives of people living with breathing disorders. pDx represents a major step forward in personalized respiratory care,” electronRx Founder/CEO Dr. Bipin Patel said.

The pDx app and complementary clinical dashboard aim to improve detecting, monitoring, and treating CRDs including asthma, COPD, interstitial lung disease, and pulmonary hypertension, which are the third leading cause of death, globally, according to a 2023 study.

The app expands upon electronRx’s proprietary purpleDx technology, adding tailored questionnaires and access to real-time detailed results for patients and clinicians. In addition to purpleDx’s mobile phone accessibility, pDx can now be accessed using any device with a screen, such as a laptop or tablet, depending on the individual’s preference. 

The technology leverages the device’s camera sensors to capture and measure blood flow biomechanics, generating digital biomarkers that translate into clinically actionable metrics. These include key physiological metrics such as heart rate, respiratory rate, and tidal volume. The data is delivered in real time to healthcare providers through a secure clinical dashboard, enabling clinicians to remotely monitor lung function and adjust treatment plans to optimize drug efficacy.

“The platform’s scalable architecture supports integration into existing care pathways, allowing for proactive intervention and reduced reliance on in-person visits,” Dr. Patel stated. “By facilitating continuous monitoring, pDx helps clinicians personalise care while improving patient adherence and reducing healthcare burden. Most importantly, it gives patients greater flexibility and control over their healthcare journey.”

electronRx uses digital technology to measure changes in lung function. Its technology unravels dynamic digital biomarkers generated from the mobile device sensors that feed into high impact actionable clinical biomarkers.

Founded in Cambridge, United Kingdom, electronRx is a deep tech company comprised of biomedical engineering, data science, machine learning, computer engineering, mathematics, physics, neuroscience, drug discovery, product development, and more; this team builds the interface between technology, the human body, and healthcare organizations that will transform healthcare is delivered and disease is treated.